Bicycle Therapeutics logo

BCYC - Bicycle Therapeutics News Story

$14.15 0.7  5.1%

Last Trade - 06/04/20

Sector
Healthcare
Size
Small Cap
Market Cap £208.2m
Enterprise Value £132.9m
Revenue £11.3m
Position in Universe 3189th / 6312

BUZZ-Bicycle Therapeutics: Clocks record rise after GS upgrades to 'buy'

Wed 11th September, 2019 5:27pm
** Shares of cancer drugs developer Bicycle Therapeutics PLC
 BCYC.O  jump 33.9% to $9.410, set for their best intraday pct
gain ever 
    ** Goldman Sachs upgrades stock to "buy" from "neutral";
cites co's fundamentals, as well as potential upside in its lead
drug
    ** "We expect BCYC to present data at as many as three
upcoming scientific meetings, thereby providing opportunities
for increased visibility and confidence in BCYC's efforts"-
Goldman Sachs  
    ** Stock at its highest since late-July
    ** All 4 brokerages covering the stock rate it at "buy" or
higher, according to Refinitiv data
    ** Stock down about 62.2% since listing in May, as of its
last close

 (Reporting by Ambar Warrick in Bengaluru)
 ((Ambar.Warrick@thomsonreuters.com; +91-80-6749-6625; Reuters
Messaging: ambar.warrick.thomsonreuters.com@reuters.net))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.